Skip to content

Allogene Therapeutics ALLO Investment Proceeds

Investment Proceeds at other companies

Precigen logo
PrecigenPGEN
$55.1M+1,105%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$175.5K
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$50M-1.0%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$3M
Janux Therapeutics logo
Janux TherapeuticsJANX
$121.31M+288%
Immunome logo
ImmunomeIMNM
$0-100%

Other financials

Income statement

See full
Revenue-
Operating income-$46.1M+29.3%
Net income-$42.6M+28.7%
EPS (diluted)-$0.18+35.7%

Balance sheet

See full
Cash & equivalents$40.6M-23.0%
Total debt$81.1M-8.9%
Total equity$278.9M-27.6%
Total assets$396.0M-22.1%

Cash flow

See full
Operating cash flow-$12.9M+75.6%
CapEx$9.0K-90.9%
Free cash flow-$12.9M+75.6%

Valuation

See full
Market cap$711.02M+164%
Enterprise value$751.47M+146%

Profitability

See full
Operating margin-1,241,813.6%-2,018,140pp
Net margin-1,170,863.6%-2,007,890pp
FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full
Return on equity-52.3%-5.7pp
Debt / equity0.3×+0.1×
Current ratio9.6×-0.1×

Where this comes from

Reported directly by Allogene Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities.

The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Allogene Therapeutics's investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Allogene Therapeutics's investment proceeds?
Allogene Therapeutics (ALLO) reported investment proceeds of $72.12M in Q1 2026.
How has Allogene Therapeutics's investment proceeds changed year-over-year?
Allogene Therapeutics's investment proceeds increased by 27.6% year-over-year, from $56.5M to $72.12M.
What does investment proceeds mean?
Cash received from sales, maturities, and redemptions of investment securities across all categories.